Research graph
References from EFFECTIVENESS AND SAFETY OF BIOSIMILAR ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR FOR RETINAL DISEASES. Local targets link to admitted publications; unresolved targets remain external evidence.
Clinical pharmacology of intravitreal anti-VEGF drugs
2018 · External reference
Anti-vascular endothelial growth factor biosimilars in ophthalmology
10.1097/iae.0000000000003626 · 2022 · External reference
Future of anti-VEGF: biosimilars and biobetters
10.1186/s40942-021-00343-3 · 2022 · External reference
A systematic review of U.S. biosimilar approvals: what evidence does the FDA require and how are manufacturers responding?
2017 · External reference
Aflibercept biosimilars – update on the development progress
2023 · External reference
Randomised, double-blind, comparative clinical study of new ranibizumab biosimilar in neovascular (Wet) age-related macular degeneration
10.2147/opth.s307746 · 2021 · External reference
Biosimilar SB11 versus reference ranibizumab in neovascular age-related macular degeneration: 1-year phase III randomised clinical trial outcomes
10.1136/bjophthalmol-2021-319637 · 2023 · External reference
Efficacy and safety of biosimilar FYB201 compared with ranibizumab in neovascular age-related macular degeneration
10.1016/j.ophtha.2021.04.031 · 2022 · External reference
Randomized trial of biosimilar XSB-001 versus reference ranibizumab in patients with neovascular age-related macular degeneration
10.1016/j.oret.2023.05.005 · 2023 · External reference
The revised JBI critical appraisal tool for the assessment of risk of bias for randomized controlled trials
10.11124/jbies-22-00430 · 2023 · External reference
Methodological quality of case series studies: an introduction to the JBI critical appraisal tool
2020 · External reference
GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables
10.1016/j.jclinepi.2010.04.026 · 2011 · External reference
Transforming scales of measurement of visual acuity at the group level
10.1111/j.1475-1313.2010.00766.x · 2010 · External reference
Visual outcomes, safety profile and morphometric response of optical coherence tomography biomarkers to ranibizumab biosimilar treatment in neovascular age-related macular degeneration: real-world evidence
10.4103/ijo.ijo_2977_20 · 2021 · External reference
A multicenter, retrospective study (RE-ENACT 2) on the use of RazumabTM (world's first biosimilar ranibizumab) in wet age-related macular degeneration
10.1007/s40123-019-00228-7 · 2020 · External reference
A multicenter, retrospective study (RE-ENACT 2) on RazumabTM (world's first biosimilar ranibizumab) in retinal vein occlusion
10.1007/s40123-020-00277-3 · 2020 · External reference
Real-life clinical effectiveness of Razumab® (the world's first biosimilar of ranibizumab) in retinal vein occlusion: a subgroup analysis of the pooled retrospective RE-ENACT study
10.1159/000488602 · 2019 · External reference
Ranibizumab biosimilar (Razumab) vs innovator ranibizumab (Lucentis) in neovascular age-related macular degeneration (n-AMD)- efficacy and safety (BIRA study)
2022 · External reference
Safety and efficacy of RazumabTM (world's first biosimilar ranibizumab) in wet age-related macular degeneration: a post-marketing, prospective ASSET study
10.1186/s40942-021-00293-w · 2021 · External reference
A prospective, randomized, parallel group, double blind, multicenter study to compare the efficacy, safety and immunogenicity of Lupin's ranibizumab with Lucentis ® in patients with neovascular age-related macular degeneration
10.4103/ijo.ijo_2118_21 · 2022 · External reference
Efficacy and safety of a new ranibizumab biosimilar CKD-701 using a pro re nata treatment regimen in neovascular age-related macular degeneration: a phase 3 randomized clinical trial
10.1371/journal.pone.0275611 · 2022 · External reference
Clinical efficacy and safety of razumab® (CESAR) study: our experience with the world's first biosimilar ranibizumab
10.4103/ijo.ijo_2516_20 · 2021 · External reference
Comparison between ranibizumab biosimilar, innovator ranibizumab and bevacizumab in a real-world situation
10.1007/s40123-021-00416-4 · 2022 · External reference
Innovator versus biosimilar ranibizumab in polypoidal choroidal vasculopathy: real-world evidence
10.1007/s40123-022-00507-w · 2022 · External reference
Biosimilar versus innovator molecule of ranibizumab in neovascular age-related macular degeneration (The BALANCE trial): real-world evidence
10.2147/opth.s407219 · 2023 · External reference
Comparison of innovator vs. biosimilar ranibizumab in treating diabetic macular edema: a multicenter retrospective study
10.1007/s40123-022-00463-5 · 2022 · External reference
Efficacy and safety of the aflibercept biosimilar SB15 in neovascular age-related macular degeneration: a phase 3 randomized clinical trial
10.1001/jamaophthalmol.2023.2260 · 2023 · External reference
Visual outcome and fluid changes between eyes with polypoidal choroidal vasculopathy receiving biosimilar CKD-701 or reference ranibizumab therapy: a post hoc analysis of a phase 3 randomized clinical trial
10.1080/02713683.2024.2323506 · 2024 · External reference
Efficacy, safety and immunogenicity of Sun's ranibizumab biosimilar in neovascular age-related macular degeneration: a phase 3, double-blind comparative study
10.1007/s40123-024-00883-5 · 2024 · External reference
Comparison of the efficacy and safety of SCD411 and reference aflibercept in patients with neovascular age-related macular degeneration
10.1038/s41598-024-65815-6 · 2024 · External reference
Evaluating the efficacy and safety of aflibercept biosimilar (P041) compared with originator product in patients with neovascular age-related macular degeneration
10.1016/j.oret.2024.02.012 · 2024 · External reference
Efficacy and safety of biosimilar QL1207 vs. the reference aflibercept for patients with neovascular age-related macular degeneration: a randomized phase 3 trial
10.1007/s40123-023-00836-4 · 2024 · External reference
Aflibercept biosimilar MYL-1701P vs reference aflibercept in diabetic macular edema: the INSIGHT randomized clinical trial
10.1001/jamaophthalmol.2024.3458 · 2024 · External reference
Biosimilar candidate CT-P42 in diabetic macular edema: 24-week results from a randomized, active-controlled, phase III study
10.1016/j.oret.2024.06.013 · 2024 · External reference
Factors of anti-vascular endothelial growth factor therapy withdrawal in patients with neovascular age-related macular degeneration: implications for improving patient adherence
10.3390/jcm10143106 · 2021 · External reference
Optimizing anti-VEGF treatment outcomes for patients with neovascular age-related macular degeneration
2018 · External reference
Impact of out-of-pocket costs on patient initiation, adherence and persistence rates for patients treated with anti-vascular endothelial growth factor medicines
10.1111/ceo.13706 · 2020 · External reference
Cost-effectiveness analysis of ranibizumab biosimilar for neovascular age-related macular degeneration in Japan
10.1007/s40123-023-00715-y · 2023 · External reference
The economics of biosimilars and challenges to biosimilar adoption in low- and middle-income countries
10.1080/14712598.2023.2247972 · 2023 · External reference
Insulin prices, availability and affordability in 13 low-income and middle-income countries
10.1136/bmjgh-2019-001410 · 2019 · External reference
The role of generic medicines and biosimilars in oncology in low-income countries
10.1093/annonc/mdt326 · 2013 · External reference
The biosimilar paradox: how anti-vascular endothelial growth factor biosimilars could increase patient and overall health care costs
10.1016/j.ophtha.2023.04.019 · 2023 · External reference
The cost savings of biosimilars can help increase patient access and lift the financial burden of health care systems
10.1016/j.semarthrit.2021.11.009 · 2022 · External reference
Biosimilar cost savings in the United States: initial experience and future potential
2018 · External reference
